167 related articles for article (PubMed ID: 35583812)
1. Multidimensional Immune Profiling of Cutaneous Lupus Erythematosus In Vivo Stratified by Patient Response to Antimalarials.
Patel J; Vazquez T; Chin F; Keyes E; Yan D; Diaz D; Grinnell M; Sharma M; Li Y; Feng R; Sprow G; Dan J; Werth VP
Arthritis Rheumatol; 2022 Oct; 74(10):1687-1698. PubMed ID: 35583812
[TBL] [Abstract][Full Text] [Related]
2. Increased CD69+CCR7+ circulating activated T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials.
Zeidi M; Chen KL; Patel J; Desai K; Kim HJ; Chakka S; Lim R; Werth VP
Lupus; 2022 Apr; 31(4):472-481. PubMed ID: 35258358
[TBL] [Abstract][Full Text] [Related]
3. Increased Myeloid Dendritic Cells and TNF-α Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus.
Zeidi M; Kim HJ; Werth VP
J Invest Dermatol; 2019 Feb; 139(2):324-332. PubMed ID: 30227141
[TBL] [Abstract][Full Text] [Related]
4. Recent findings about antimalarials in cutaneous lupus erythematosus: What dermatologists should know.
Teboul A; Arnaud L; Chasset F
J Dermatol; 2024 Jul; 51(7):895-903. PubMed ID: 38482997
[TBL] [Abstract][Full Text] [Related]
5. Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus.
Alves P; Bashir MM; Wysocka M; Zeidi M; Feng R; Werth VP
J Investig Dermatol Symp Proc; 2017 Oct; 18(2):S57-S63. PubMed ID: 28941496
[TBL] [Abstract][Full Text] [Related]
6. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.
Chasset F; Arnaud L; Costedoat-Chalumeau N; Zahr N; Bessis D; Francès C
J Am Acad Dermatol; 2016 Apr; 74(4):693-9.e3. PubMed ID: 26850655
[TBL] [Abstract][Full Text] [Related]
7. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
[TBL] [Abstract][Full Text] [Related]
8. Effect of
Gardet A; Pellerin A; McCarl CA; Diwanji R; Wang W; Donaldson D; Franchimont N; Werth VP; Rabah D
Front Immunol; 2019; 10():275. PubMed ID: 30846987
[No Abstract] [Full Text] [Related]
9. Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis.
Chasset F; Bouaziz JD; Costedoat-Chalumeau N; Francès C; Arnaud L
Br J Dermatol; 2017 Jul; 177(1):188-196. PubMed ID: 28112801
[TBL] [Abstract][Full Text] [Related]
10. Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study.
Ikeda T; Kanazawa N; Furukawa F
J Dermatol; 2012 Jun; 39(6):531-5. PubMed ID: 22168306
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous Toll-like Receptor 9 Pre-Defines Hydroxychloroquine Dosage in Patients with Both Discoid and Subacute Lupus Erythematosus.
Englert KA; Dyduch G; Kłosowicz A; Spałkowska M; Jaworek AK; Migacz-Gruszka K; Jarosz-Chudek A; Mercuri SR; Szpor J; Mazzoccoli G; Damiani G; Wojas-Pelc A
Medicina (Kaunas); 2023 Nov; 59(11):. PubMed ID: 38004071
[No Abstract] [Full Text] [Related]
12. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.
Chang AY; Piette EW; Foering KP; Tenhave TR; Okawa J; Werth VP
Arch Dermatol; 2011 Nov; 147(11):1261-7. PubMed ID: 21768444
[TBL] [Abstract][Full Text] [Related]
13. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.
Cavazzana I; Sala R; Bazzani C; Ceribelli A; Zane C; Cattaneo R; Tincani A; Calzavara-Pinton PG; Franceschini F
Lupus; 2009 Jul; 18(8):735-9. PubMed ID: 19502270
[TBL] [Abstract][Full Text] [Related]
14. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.
Mittal L; Zhang L; Feng R; Werth VP
J Am Acad Dermatol; 2018 Jan; 78(1):100-106.e1. PubMed ID: 28989103
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus.
Stannard JN; Kahlenberg JM
Curr Opin Rheumatol; 2016 Sep; 28(5):453-9. PubMed ID: 27270345
[TBL] [Abstract][Full Text] [Related]
16. Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial.
Yokogawa N; Eto H; Tanikawa A; Ikeda T; Yamamoto K; Takahashi T; Mizukami H; Sato T; Yokota N; Furukawa F
Arthritis Rheumatol; 2017 Apr; 69(4):791-799. PubMed ID: 27992698
[TBL] [Abstract][Full Text] [Related]
17. Candidate drug replacements for quinacrine in cutaneous lupus erythematosus.
Yan D; Borucki R; Sontheimer RD; Werth VP
Lupus Sci Med; 2020 Oct; 7(1):. PubMed ID: 33082164
[TBL] [Abstract][Full Text] [Related]
18. Impact of smoking in cutaneous lupus erythematosus.
Piette EW; Foering KP; Chang AY; Okawa J; Ten Have TR; Feng R; Werth VP
Arch Dermatol; 2012 Mar; 148(3):317-22. PubMed ID: 22105815
[TBL] [Abstract][Full Text] [Related]
19. Hydroxychloroquine does not impair antibody response to 13-valent pneumococcal conjugate vaccine in patients with cutaneous lupus erythematosus-A pilot study.
Pelka K; Matyja-Bednarczyk A; Wojas-Pelc A; Pastuszczak M
Dermatol Ther; 2021 Jul; 34(4):e15013. PubMed ID: 34056799
[TBL] [Abstract][Full Text] [Related]
20. Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus.
Ezra N; Jorizzo J
Clin Exp Dermatol; 2012 Jun; 37(4):327-34. PubMed ID: 22582908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
